Check the envelope on your counter
Wednesday, 4:15 PM, a pharmacy counter on Amsterdam Avenue.
Three people ahead of him in the pickup line, and a man of about sixty-eight had decided to use the wait productively. Navy windbreaker, reading glasses pushed up into his hair, a thick envelope from his drug plan already torn open along one edge.
He pulled the pages out, held them at arm's length toward the ceiling light, and read. Four lines, maybe five. I counted.
Then he folded the whole thing into quarters, slid it into his jacket pocket, and stepped up to collect three prescriptions. I have watched people study a wine list with more suspicion.
The envelope was not the tell. The fold was. He never turned to page two.
SEEING THROUGH
The Arm's-Length Read
THE TAPE
EVIDENCE: MIXED ■■□ · Official figures firm, access study descriptive and industry-funded.
That envelope is in tens of millions of mailboxes this month. Plans have to get the notice into an enrollee's hands by September 30, and it lists everything changing on January 1. This year's version was written under new arithmetic. On July 28, 2026, CMS announced it is ending the program that has been holding standalone drug plan premiums down, discontinuing it at the end of this year. The base premium goes from $38.99 to $41.33; the average plan bid from $239.27 to $296.05. Plan-by-plan numbers arrive later this month; the window to change anything runs October 15 to December 7.
Underneath
From the business to the body
Three researchers pulled the January drug lists for 2024, 2025 and 2026 and tracked 59 brand-name drugs across 16 crowded treatment classes, the ones where a plan has several similar drugs to choose between. They measured how many enrollees had each drug covered. In standalone drug plans the average fell from 47% to 36%, about 12 points. In Medicare Advantage drug plans, from 52% to 46%. Commercial coverage barely moved.
Two cautions, both real. The study counted coverage, not harm; it followed no patients. And the authors work for a research group funded by drug makers, who have their own interest in counting exclusions.
Pushing the other way: the same law caps what you pay for covered drugs at $2,100 this year. And cutting doses over cost is uncommon past sixty-five — roughly 2 people in 100.
From the balance sheet to you
Not investment advice. I hold no positions in anything named here.
Find the envelope. It is on the counter, in the pile with the catalogues, or already halfway to the recycling. Open it to the section about drugs and put your glasses on properly, because this is small type doing expensive work. Go down your own medicines, one at a time. Write down any that changed tier — the plan's price group — gained a rule, or disappeared.
Field Prescription
One action. Then take it to a professional.
Turn to the drug list and check every medicine you take against it, price group included. Then ask:
1. Which of my drugs changed group or came off the list?
2. What would those drugs cost under the other plans in my area?
3. If one is gone, what is the covered alternative?
File status: open
What I cannot tell you is the only thing that matters: what your plan did. The full set of plan-by-plan numbers lands in the second half of September, and your own letter is the only document written about you. Most people never compare. The plans know that number as well as I do.
